THE CATEGORY
IS GETTING ATTENTION.

Single Dose lists SD-A001 in preclinical development for disorders of maladaptive learning. The company describes a neuroadaptive approach. This is a company-reported development program, not an approved medicine.

Single Dose’s founder and CEO previously worked as a Drug Product Lead at Gilead on complex injectable and inhalation programs, according to the company biography. He is not an Antaeus adviser or collaborator.

WO2025040956A2 names Davin Rautiola as inventor and discloses bromantane-related preparations and stimulant-addiction uses. A published PCT application is not a granted worldwide patent or an efficacy result. We have not independently established that SD-A001 is bromantane.

PMID 15500036 ↗ reports gene-expression findings in rat brain for Ladasten. The compound, tissue and endpoint differ from the Bemitil heat program. It supplies a related research precedent, not transferable proof.

Our first question combines Bemitil molecular profiling with a controlled heat-performance endpoint. We make no superiority, affiliation, endorsement or freedom-to-operate claim from another company’s development.